These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

464 related items for PubMed ID: 17250692

  • 1. Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection.
    Cruz AA, Lima F, Sarinho E, Ayre G, Martin C, Fox H, Cooper PJ.
    Clin Exp Allergy; 2007 Feb; 37(2):197-207. PubMed ID: 17250692
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.
    Vignola AM, Humbert M, Bousquet J, Boulet LP, Hedgecock S, Blogg M, Fox H, Surrey K.
    Allergy; 2004 Jul; 59(7):709-17. PubMed ID: 15180757
    [Abstract] [Full Text] [Related]

  • 3. Geohelminth infections: a review of the role of IgE and assessment of potential risks of anti-IgE treatment.
    Cooper PJ, Ayre G, Martin C, Rizzo JA, Ponte EV, Cruz AA.
    Allergy; 2008 Apr; 63(4):409-17. PubMed ID: 18315729
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality.
    Holgate S, Bousquet J, Wenzel S, Fox H, Liu J, Castellsague J.
    Curr Med Res Opin; 2001 Apr; 17(4):233-40. PubMed ID: 11922396
    [Abstract] [Full Text] [Related]

  • 5. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.
    Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, Gupta N.
    J Allergy Clin Immunol; 2001 Aug; 108(2):184-90. PubMed ID: 11496232
    [Abstract] [Full Text] [Related]

  • 6. Monoclonal anti-IgE antibody: a novel therapy for allergic airways disease.
    Berger WE.
    Ann Allergy Asthma Immunol; 2002 Feb; 88(2):152-60; quiz 161-2, 208. PubMed ID: 11868919
    [Abstract] [Full Text] [Related]

  • 7. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma.
    Kopp MV, Hamelmann E, Zielen S, Kamin W, Bergmann KC, Sieder C, Stenglein S, Seyfried S, Wahn U, DUAL study group.
    Clin Exp Allergy; 2009 Feb; 39(2):271-9. PubMed ID: 19016798
    [Abstract] [Full Text] [Related]

  • 8. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis.
    Casale TB, Busse WW, Kline JN, Ballas ZK, Moss MH, Townley RG, Mokhtarani M, Seyfert-Margolis V, Asare A, Bateman K, Deniz Y, Immune Tolerance Network Group.
    J Allergy Clin Immunol; 2006 Jan; 117(1):134-40. PubMed ID: 16387596
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.
    Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H.
    Allergy; 2004 Jul; 59(7):701-8. PubMed ID: 15180756
    [Abstract] [Full Text] [Related]

  • 10. Effect of omalizumab on the need for rescue systemic corticosteroid treatment in patients with moderate-to-severe persistent IgE-mediated allergic asthma: a pooled analysis.
    Busse WW, Massanari M, Kianifard F, Geba GP.
    Curr Med Res Opin; 2007 Oct; 23(10):2379-86. PubMed ID: 17711616
    [Abstract] [Full Text] [Related]

  • 11. Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma.
    Kulus M, Hébert J, Garcia E, Fowler Taylor A, Fernandez Vidaurre C, Blogg M.
    Curr Med Res Opin; 2010 Jun; 26(6):1285-93. PubMed ID: 20377320
    [Abstract] [Full Text] [Related]

  • 12. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
    Niven R, Chung KF, Panahloo Z, Blogg M, Ayre G.
    Respir Med; 2008 Oct; 102(10):1371-8. PubMed ID: 18657960
    [Abstract] [Full Text] [Related]

  • 13. Reduction of the total IgE level by omalizumab in children and adolescents.
    Steiss JO, Strohner P, Zimmer KP, Lindemann H.
    J Asthma; 2008 Apr; 45(3):233-6. PubMed ID: 18415832
    [Abstract] [Full Text] [Related]

  • 14. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis.
    Chervinsky P, Casale T, Townley R, Tripathy I, Hedgecock S, Fowler-Taylor A, Shen H, Fox H.
    Ann Allergy Asthma Immunol; 2003 Aug; 91(2):160-7. PubMed ID: 12952110
    [Abstract] [Full Text] [Related]

  • 15. Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils.
    Lin H, Boesel KM, Griffith DT, Prussin C, Foster B, Romero FA, Townley R, Casale TB.
    J Allergy Clin Immunol; 2004 Feb; 113(2):297-302. PubMed ID: 14767445
    [Abstract] [Full Text] [Related]

  • 16. Relationship between pretreatment specific IgE and the response to omalizumab therapy.
    Wahn U, Martin C, Freeman P, Blogg M, Jimenez P.
    Allergy; 2009 Dec; 64(12):1780-7. PubMed ID: 19627273
    [Abstract] [Full Text] [Related]

  • 17. Anti-immunoglobulin E therapy with omalizumab for asthma.
    Hendeles L, Sorkness CA.
    Ann Pharmacother; 2007 Sep; 41(9):1397-410. PubMed ID: 17698897
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase.
    Maurer M, Altrichter S, Bieber T, Biedermann T, Bräutigam M, Seyfried S, Brehler R, Grabbe J, Hunzelmann N, Jakob T, Jung A, Kleine-Tebbe J, Mempel M, Meurer M, Reich K, Ruëff F, Schäkel K, Sengupta K, Sieder C, Simon JC, Wedi B, Zuberbier T, Mahler V, Staubach P.
    J Allergy Clin Immunol; 2011 Jul; 128(1):202-209.e5. PubMed ID: 21636116
    [Abstract] [Full Text] [Related]

  • 19. Omalizumab: a novel therapy for allergic asthma.
    Davis LA.
    Ann Pharmacother; 2004 Jul; 38(7-8):1236-42. PubMed ID: 15187202
    [Abstract] [Full Text] [Related]

  • 20. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy.
    Holgate ST, Djukanović R, Casale T, Bousquet J.
    Clin Exp Allergy; 2005 Apr; 35(4):408-16. PubMed ID: 15836747
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.